Content about therapy for hemophilia

January 7, 2013

Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

WESTON, Mass. — Biogen Idec is seeking Food and Drug Administration approval for a hemophilia drug that it called the first of its kind.

The drug maker announced that it had submitted a regulatory application for recombinant factor IX Fc fusion protein, or rFIXFc, which it called the first long-lasting factor IX therapy for hemophilia B.